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Background: The prognostic role of the arterial blood gas tension of carbon dioxide (PaCO2) in severe Chronic
Obstructive Pulmonary Disease (COPD) remains unknown. The aim of this study was to estimate the association
between PaCO2 and mortality in oxygen-dependent COPD.
Methods: National prospective study of patients starting long-term oxygen therapy (LTOT) for COPD in Sweden
between October 1, 2005 and June 30, 2009, with all-cause mortality as endpoint. The association between PaCO2
while breathing air, PaCO2 (air), and mortality was estimated using Cox regression adjusted for age, sex, arterial
blood gas tension of oxygen (PaO2), World Health Organization performance status, body mass index, comorbidity,
and medications.
Results: Of 2,249 patients included, 1,129 (50%) died during a median 1.1 years (IQR 0.6-2.0 years) of observation.
No patient was lost to follow-up. PaCO2 (air) independently predicted adjusted mortality (p < 0.001). The association
with mortality was U-shaped, with the lowest mortality at approximately PaCO2 (air) 6.5 kPa and increased mortality
at PaCO2 (air) below 5.0 kPa and above 7.0 kPa.
Conclusion: In oxygen-dependent COPD, PaCO2 (air) is an independent prognostic factor with a U-shaped association
with mortality.
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Advanced chronic obstructive pulmonary disease (COPD)
is associated with high morbidity and mortality [1]. Al-
though long-term oxygen therapy (LTOT) decreases mor-
tality in patients with advanced COPD and chronic
hypoxemia [2,3], the prognosis is poor with a mortality
rate of 51% at 2 years [4]. Predictors of mortality in
oxygen-dependent COPD include sex, age, body mass
index (BMI), comorbidities, forced expiratory volume in
one second (FEV1), and arterial blood gas tension of
oxygen (PaO2) [5-14].
The prognostic role of PaCO2 in oxygen-dependent
COPD remains unknown. PaCO2 while breathing air,
PaCO2 (air), has been associated with both increased* Correspondence: zai.ahmd@gmail.com
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unless otherwise stated.mortality [5], decreased mortality [15], and no associ-
ation with mortality [4,16].
Defining the predictive role of PaCO2 (air) on mortal-
ity is important for several reasons. Despite the data
being inconsistent, clinicians often regard hypercapnia
(PaCO2 > 6.5 kPa) as an indicator of more severe re-
spiratory disease, worse prognosis, and higher risk of
complications from oxygen therapy including respira-
tory depression. High-flow oxygen given pre-hospital to
patients with likely COPD exacerbation was recently
associated with increased risk of acute hypercapnia and
mortality [17]. Guidelines recommend titration of oxygen
dose in hospital to avoid possible adverse effects when
LTOT is initiated in a patient with hypercapnia [18].
Hypercapnia might indicate the presence of a concurrent
hypoventilation syndrome in COPD, which is associated
with shorter survival [19]. In addition, knowledge onl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for patients with oxygen-dependent COPD is lacking.
The aim of this nationwide prospective study was
therefore to estimate the association between PaCO2
(air) and mortality in oxygen-dependent COPD.
Materials and methods
We prospectively included patients from the National
Register for Long Term Oxygen Therapy (Swedevox)
with physician-diagnosed COPD who started LTOT be-
tween October 1, 2005 and June 30, 2009. Swedevox is a
health quality register run by the health professionals
and with financial support from the government. Swede-
vox has a population-based coverage of approximately
85% of patients starting LTOT in Sweden since 1987
[20]. Details of the register were described in a recently
published study using the same database [21]. For pa-
tients who had started LTOT more than once (n = 62),
only the most recent treatment episode was included in
the analysis. Exclusion criterion was a diagnosis of lung
cancer before starting LTOT (baseline).
Data on comorbidity and time spent in hospital during
the four-year period before baseline were obtained from
the National Patient Register for in- and outpatient care
[22]. Diagnoses were coded according to the ninth
(before 1997) [23] and tenth revisions of the International
Classification of Disease (ICD) [24]. Possible comorbid
hypoventilation was defined as hypoxia with a normal
alveolar-arterial oxygen tension difference, (P[A-a]O2),
of < 3 kPa, or a prior diagnosis (ICD-9; ICD-10) which
may cause hypoventilation [25]: scoliosis (737.4; M41),
spinal muscular atrophy (335.1; G12), muscular dystrophy
(335.2; G71), myasthenia gravis (358; G70), post-polio syn-
drome (138; G14), sequelae of poliomyelitis (B91.9), se-
quelae of respiratory tuberculosis (137; B90.9), obstructive
sleep apnea (327.2; G47.3), obesity hypoventilation syn-
drome (278.0; E66.2), or prolonged mechanical ventilation
(DG008, AG063; 93.90, 96.70).
Data on all dispensed drug prescriptions in outpatient
care after July 1, 2005 were obtained from the Swedish
Prescribed Drug Register [26]. Patients were followed
until withdrawal of LTOT, death, or December 31, 2009,
whichever came first. The primary endpoint was all-
cause mortality, obtained from the Swedish Causes of
Death Register.
All patients participating in the study were informed
according to directives from the authorities. The study
was approved by all the relevant ethics committees in
Sweden, the Swedish National Board of Health and
Welfare, and the Swedish Data Inspection Board.
Statistical analysis
Baseline patient characteristics were summarized using
mean with standard deviation (SD) and median withrange or interquartile range (IQR) for continuous vari-
ables with normal and skewed distribution, respectively.
Categorical variables were expressed as frequencies and
percentages. The differences among the groups were
tested with t-test for continuous variables and chi-
square test for categorical variables.
Missing elements were imputed for PaO2 (air) (n = 289),
PaCO2 (air) (n = 301), PaO2 (oxygen) (n = 210), PaCO2
(oxygen) (n = 213), FEV1 (n = 849), and body mass index
(BMI) (n = 701), as previously described [21]. The model
estimates were robust to the imputations. P[A-a]O2 was
calculated using the alveolar gas equation: P[A-a]O2 =
PiO2 - (PaCO2/R) - PaO2. Change in PaCO2 was defined
as a difference between PaCO2 (oxygen) and PaCO2 (air)
of 0.3 kPa or more.
Association between PaCO2 (air) and mortality was
estimated using Cox multiple regression, adjusting for
baseline age, sex, PaO2 (air), World Health Organization
(WHO) performance status, BMI, number of cardiovas-
cular diagnoses (cerebrovascular disease, heart failure,
hypertension, ischemic heart disease, peripheral artery
disease, pulmonary embolism, and other circulatory dis-
ease), treatment with oral glucocorticoids, benzodiaze-
pines, and opioids. The model included a linear and a
squared term for PaCO2 (air) to evaluate nonlinear asso-
ciations. Higher-order terms did not improve the model
with regard to diagnostics. Mortality estimates were
expressed as hazard ratios (HRs) with 95% confidence
intervals (CIs). Statistical significance was defined as a
two-sided p-value of < 0.05.
Statistical analyses were conducted using the software
packages Stata, version 12 (StataCorp LP; College Station,
TX), and SAS, version 9.2 (SAS Institute, Inc., Cary, NC).
Results
A total of 2,249 patients were included. No patient was
lost to follow-up. The cohort generated 3,118 person-
years at risk during a median 1.1 years (IQR, 0.6–2.0 years)
of follow-up. During this time, 1,129 (50%) patients died.
The main causes of death were respiratory disease (68%),
cardiovascular disease (20%), and cancer (6%). LTOT was
withdrawn for other reasons than death in 138 (6%)
patients, mainly because of improved oxygenation.
Patient characteristics at baseline are shown in Table 1.
Hypercapnia (PaCO2 (air) > 6.5 kPa) was present in 39%
of patients. After initiating LTOT, PaCO2 increased in
45% of patients, decreased in 19%, and remained un-
changed (difference less than 0.3 kPa) in 36%. Of
patients with hypercapnia, 37% increased in PaCO2 after
starting LTOT, whereas 30% decreased to a PaCO2
below 6.5 kPa.
Hypercapnic patients were prescribed a slightly lower
median oxygen dose than normocapnic patients, 1 (IQR,
1–1.5) vs. 1.5 (IQR, 1–2) l/min (p < 0.001). In total, 29%
Table 1 Patient characteristics at baseline
Characteristic All patients, n = 2,249
Age, years 74.7 ± 8.2
Male/female gender 921/1328
PaO2 (air), kPa 6.5 ± 0.9
PaCO2 (air), kPa 6.3 ± 1.2
PaO2 (oxygen), kPa 8.7 ± 1.1
PaCO2 (oxygen), kPa 6.5 ± 1.3
FEV1
† 0.71 (0.6 - 1.0)
Known ever to smoke, n (%) 2.106 (94)
Body mass index, n (%)
< 18.5 280 (13)
18.5 – 24.9 1397 (62)
25 – 29.9 338 (15)
≥ 30 234 (10)












Data presented as mean ± SD unless otherwise specified. Hospitalizations
and diagnoses were assessed within the four-year period before the start of
long-term oxygen therapy (LTOT).
†Median (first quartile – third quartile).
Abbreviations: FEV1, forced expiratory volume in one second.
Table 2 Cox regression of all-cause mortality in 2,249
patients on long-term oxygen therapy for COPD
Parameter Hazard ratio 95% CI P-value
PaCO2 (air)† - - < 0.001
Age (per y) 1.04 1.03 – 1.05 < 0.001
Male 1.35 1.19 – 1.53 < 0.001
BMI < 0.001*
< 18.5 1.35 1.14 – 1.60 < 0.001
18.5- 24.9 Ref - -
25 - 29.9 0.73 0.60 – 0.88 0.001
≥ 30 0.80 0.64 – 1.00 0.051
WHO performance status < 0.001*
0 Ref - -
1 1.01 0.74 – 1.39 0.927
2 1.47 1.08 – 2.01 0.016
3 2.26 1.62 – 3.16 < 0.001
4 3.21 1.94 – 5.30 < 0.001
Missing 1.35 0.95 – 1.93 0.098
PaO2 (air) (per 1 kPa) 0.91 0.85 – 0.98 0.014
Cardiovascular diagnoses < 0.001*
0 Ref - -
1 1.25 1.08 – 1.46 0.003
2 1.42 1.20 – 1.68 < 0.001
> 2 1.38 1.12 – 1.71 0.003
Oral glucocorticoids 1.16 1.02 – 1.31 < 0.001
Opioids 1.19 1.05 – 1.35 0.009
Benzodiazepines 1.18 1.03 – 1.34 0.014
*Wald test of total significance for class variables with more than two categories.
†The p-value is reported for both linear and squared term for PaCO2 (air).
Abbreviations: CI, confidence interval; Ref, reference category.
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proportion of patients with hypercapnia (31%) than
normocapnic patients (27%) started LTOT in hospital
(p = 0.039).
Effects on mortality
PaCO2 (air) independently predicted adjusted mortality
(p < 0.001), as shown in Table 2. The association with
mortality exhibited a U-shaped pattern, with lowest mor-
tality at approximately PaCO2 (air) 6.5 kPa and increased
mortality below 5.0 kPa and above 7.0 kPa (Figure 1).
Compared to a PaCO2 (air) of 6.5 kPa, a PaCO2 (air)
of ≤ 4.5 kPa increased mortality by 17% or more, and a
PaCO2 (air) of ≥ 8.0 kPa increased mortality by at least
15%. Excluding patients with possible hypoventilation
(n = 122) did not alter the estimates. Sensitivity analysis
only including patients with FEV1/FVC < 0.7 did not
alter the results.P[A-a]O2 did not predict adjusted mortality (p = 0.342),
when included instead of PaO2 and PaCO2. Changes in
PaCO2 when starting LTOT did not affect adjusted
mortality; neither a rise in PaCO2 (p = 0.227) or a fall in
PaCO2 (p = 0.355).
Discussion
The novel finding in the present study is that PaCO2
(air) has an U-shaped association with mortality in
oxygen-dependent COPD. PaCO2 (air) values lower than
5.0 kPa and higher than 7.0 kPa were associated with
increased mortality.
Previous findings on the association between PaCO2
and mortality have been conflicting. Our results are con-
sistent with studies reporting increased mortality associ-
ated with either hypocapnia [5,27] or hypercapnia
[3,28,29]. In a large study of COPD patients on LTOT,
Chailleux et al. found PaCO2 to be an independent
negative predictor at 3 years follow-up [5]. However,
Aida and colleagues found no association between
Figure 1 PaCO2 and adjusted mortality in oxygen-dependent COPD. Hazard ratio of death for different levels of PaCO2 (air) compared to at
PaCO2 (air) = 6.5 kPa, adjusted for age, sex, PaO2 (air), WHO performance status, BMI, number of cardiovascular diagnoses, and treatment with oral
glucocorticoids, benzodiazepines and opioids. Abbreviations: PaCO2 (air), Arterial blood gas tension of carbon dioxide on air; PaO2 (air), Arterial
blood gas tension of oxygen on air; WHO, World Health Organization; BMI, Body Mass Index.
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studies, to our knowledge, evaluated the shape of the
association, the discrepancy between the findings of
previous studies may partly owe to that they did not ac-
count for a nonlinear association.
Strengths of the present study include its national
prospective design and that it included a large cohort of
both men and women with oxygen-dependent COPD.
No patient was lost to follow-up. The analysis was
adjusted for relevant confounders, including comorbidity
and exposure to benzodiazepines and opioids. A limita-
tion of the study is that we lacked data on pH and base
excess and could not evaluate the chronicity of the
respiratory failure or the level of metabolic compensation.
Nevertheless, the study presents data on the prognostic
role of PaCO2 in patients starting LTOT for COPD that
are likely to be applicable to current clinical practice.
An interesting additional finding was the large vari-
ability in the change in PaCO2 when starting LTOT.
There is concern among clinicians that the level of
PaCO2 will increase after starting LTOT, especially in
hypercapnic patients. In the present study, 30% of pa-
tients with hypercapnia actually decreased their PaCO2
to below 6.5 kPa after initiation of LTOT and PaCO2
remained unchanged in 36% of patients. This may be
explained by regression to the mean and by improving
blood gases over time in patients starting LTOT in
relation to an exacerbation. The change in PaCO2
between breathing room air and breathing oxygen
(LTOT) did not predict mortality. This suggests that
some increase in PaCO2 from baseline when starting
LTOT is well-tolerated and not associated with worse
prognosis.Which mechanisms underpin the association between
blood gas disturbances and mortality? The lack of a clear
association between P[A-a]O2 and mortality implies that
gas exchange inefficiency is not the main driver behind
the increased mortality associated with hypoxemia and
hypo- and hypercapnia. Our study suggests that the level
of alveolar ventilation predicts mortality independently
of the level of hypoxemia. Factors contributing to the in-
creasing mortality could include more severe underlying
COPD, respiratory maladaptation, and the presence of
comorbidities. In hypocapnia, increased minute ventila-
tion may cause respiratory muscle fatigue, hastened ven-
tilatory failure and death. This might reflect a relative
inability among these patients to adapt their breathing
pattern to avoid respiratory muscle fatigue. Comorbidi-
ties such as congestive heart failure or pulmonary em-
bolism may also contribute to the increased ventilation
and worse prognosis. Modest hypercapnia may reflect an
adaptive alveolar hypoventilation, which occurs (uncon-
sciously) to minimize dyspnea and respiratory muscle
fatigue. While modest hypercapnia were not associated
with earlier death, PaCO2 (air) exceeding 7.0 kPa seemed
to be maladaptive and associated with increased mortal-
ity rates. Mechanical defects of the chest wall, such as
kyphoscoliosis, and hyperinflation may predispose to
alveolar hypoventilation by imposing additional work on
the inspiratory muscles [30]. Concurrent hypoventilation
syndrome may contribute to hypercapnia in some COPD
patients, requiring treatment with home mechanical
ventilation in addition to oxygen therapy [31]. However,
it is still unclear whether long-term non-invasive home
ventilation improves prognosis in patients with stable
hypercapnic COPD [32].
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PaCO2 (air) below 5 kPa or above 7 kPa are at increased
risk of death and should be optimally treated and care-
fully followed. Furthermore, patients with hypo- or
hypercapnia should be evaluated for comorbid diseases,
including heart failure and hypoventilation syndromes.
The U-shaped association of PaCO2 (air) with overall
mortality should be validated by further studies and in-
corporated in future prognostic models of patients with
advanced COPD.
Conclusion
In conclusion, the level of alveolar ventilation, as reflected
by both hypo- and hypercapnia, predicts mortality in
oxygen-dependent COPD.
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